

Supplementary Materials

Synthesis of the Guanidine Derivative:

N-{[(7-(4,5-Dihydro-1*H*-imidazol-2-yl)-2-(*p*-tolyl)-6,7-dihydro-2*H*-imidazo[2,1-*c*][1,2,4]triazol-3(5*H*)-ylidene)amino]-(phenylamino)methylene}benzamide


Copies of IR, ¹H-NMR, ¹³C-NMR, and MS spectra of compounds 2 and 3

Łukasz Balewski ^{1,*}, Anita Kornicka ¹


¹ Department of Chemical Technology of Drugs, Faculty of Pharmacy,
Medical University of Gdańsk, 80-416 Gdańsk, Poland

* Correspondence: lukasz.balewski@gumed.edu.pl ; Tel.: +48-58-349-1952; Fax: +48-58-349-1654


N-{[7-(4,5-dihydro-1*H*-imidazol-2-yl)-2-(*p*-tolyl)-6,7-dihydro-2*H*-imidazo[2,1-*c*][1,2,4]triazol-3(5*H*)-ylidene]carbamothioyl}benzamide (**2**)




IR spectrum of **2** in KBr



¹H-NMR spectrum of **2** in DMSO-*d*₆ (500 MHz)




^{13}C -NMR spectrum of **2** in $\text{DMSO-}d_6$ + TFA (125 MHz)




MS spectrum of 2 (ESI)

<Spectrum>


Retention Time: 2.817 (Scan#: 339)
Max Peak: 449 Base Peak: 447.15 (379358)
Spectrum: Single 2.817 (339)
Background: None Polarity: Pos Segment: 1 - Event 1




N-{[(7-(4,5-dihydro-1*H*-imidazol-2-yl)-2-(*p*-tolyl)-6,7-dihydro-2*H*-imidazo[2,1-*c*][1,2,4]triazol-3(5*H*)-ylidene)amino]-
(phenylamino)methylene}benzamide (**3**)




IR spectrum of **3** in KBr



¹H-NMR spectrum of **3** in DMSO-*d*₆ (500 MHz)



^{13}C -NMR spectrum of **3** in $\text{DMSO-}d_6$ (125 MHz)



MS spectrum of 3 (ESI)

<Spectrum>

Retention Time: 2.233 (Scan#: 269)

Max Peak: 695 Base Peak: 506.25 (467051)

Spectrum: Single 2.233 (269)

Background: None Polarity: Pos Segment1 - Event1

